AbbVie Inc.

Overview

AbbVie Inc. is a global biopharmaceutical company focused on the research and development, manufacture, commercialization and sale of innovative medicines and therapies. It describes its mission as discovering and delivering innovative medicines and solutions that address complex health issues and enhance people’s lives.[1][2]

AbbVie reports approximately 57,000 employees in more than 70 countries. Its net revenue was $61.160 billion in 2025. AbbVie became an independent, publicly traded company on January 1, 2013, following its separation from Abbott Laboratories.[3]+2 [1]+4

Products & services

AbbVie’s products include medicines across immunology, neuroscience, oncology and aesthetics. Its immunology portfolio includes Skyrizi (risankizumab), used for plaque psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis; for inflammatory bowel disease, treatment includes intravenous induction followed by subcutaneous maintenance, including an on-body injector option. Rinvoq (upadacitinib) is used for several inflammatory conditions, including rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis and Crohn’s disease. Humira (adalimumab) is a subcutaneous biologic for autoimmune conditions including rheumatoid and psoriatic arthritis, Crohn’s disease and plaque psoriasis.[6]+2

Neuroscience products include Vraylar (cariprazine), for schizophrenia, bipolar I disorder and adjunctive treatment of major depressive disorder; Qulipta (atogepant), a CGRP-receptor antagonist for migraine prevention; and Vyalev (foscarbidopa/foslevodopa), a continuous 24-hour subcutaneous infusion for motor fluctuations in advanced Parkinson’s disease. Botox (onabotulinumtoxinA) is an injectable neuromuscular-blocking medicine sold for therapeutic uses such as chronic migraine and spasticity, as well as cosmetic treatment of facial lines. Oncology products include Elahere, an antibody-drug conjugate for certain FRα-positive platinum-resistant ovarian, fallopian-tube or primary-peritoneal cancers, and Imbruvica, an oral Bruton's tyrosine kinase inhibitor for certain blood cancers.[9]+6

In FY2025, worldwide sales included $17.562 billion for Skyrizi, $8.304 billion for Rinvoq, $4.540 billion for Humira, $3.769 billion for Botox Therapeutic, $3.621 billion for Vraylar and $2.602 billion for Botox Cosmetic. The reported product portfolio also includes Ubrelvy, Venclexta, Elahere, Epkinly, Juvederm Collection and Mavyret.[16][17] [6]+11

Geographic presence

In FY2025, AbbVie generated approximately 24% of its revenue outside the United States, with the remainder primarily from U.S. sales; total net revenue was $61.2 billion. The company reports product sales for the U.S. and international markets, but not a country-by-country revenue breakdown.[18]+2

AbbVie’s corporate headquarters are in North Chicago, Illinois. At year-end 2025, it owned or leased about 600 facilities worldwide, totaling approximately 19.4 million square feet for production, distribution and administration. Its listed manufacturing locations span the United States and Puerto Rico, Costa Rica, Ireland, Italy, France, Germany and Singapore.[20][21]

Research and development sites include locations across the United States, as well as facilities in Ludwigshafen, Germany, and Oxford, United Kingdom; central distribution centers are located in the United States and Europe. AbbVie reports approximately 57,000 employees in more than 70 countries and R&D and/or manufacturing facilities in about 20 countries; it does not provide employee counts by geography in the cited sources.[22][2] [18]+6

Business segments

For 2025, AbbVie reports **one operating and reportable segment**, its global pharmaceutical business; therapeutic-area and geographic disclosures are supplemental revenue views, not separate reportable segments.[23][24] By therapeutic area, 2025 net revenue was: **Immunology**, $30.406 billion (~49.7% of total); **Neuroscience**, $10.767 billion (~17.6%); **Oncology**, $6.655 billion (~10.9%); and **Aesthetics**, $4.860 billion (~7.9%). These categories encompass products including Skyrizi and Rinvoq (Immunology), Vraylar and Ubrelvy (Neuroscience), Imbruvica and Venclexta (Oncology), and Botox Cosmetic and Juvederm (Aesthetics).[4]+2 [23]+4

Company history

AbbVie’s corporate heritage traces to 1888, when Dr. Wallace C. Abbott began making medicines in a Chicago drugstore; AbbVie itself became an independent company in January 2013, following its separation from Abbott. HUMIRA, introduced in 2003, was among the important products in the company’s early history.[27]+3

In 2015, AbbVie acquired Pharmacyclics, adding IMBRUVICA to its portfolio. In 2019, the U.S. FDA approved SKYRIZI and RINVOQ, marking further milestones in its immunology portfolio. AbbVie completed its acquisition of Allergan in 2020, expanding the company into additional therapeutic areas. In 2026, it completed the acquisition of Apogee Therapeutics.[30]+4 [5]+8

Sources

• AbbVie Inc. — Full financial report (2025 Y)
  21 citations

  [1][6][7][8][9][10][11][12][13][14][15][16][17][18][20][21][22][23][24][25][26]
• www.abbvie.com[2]
• investors.abbvie.com[3]
• news.abbvie.com[4]
• AbbVie Inc. — Full financial report (2013 Y)[5][28]
• www.sec.gov[19]
• www.abbott.com[27]
• news.abbvie.com[29]
• news.abbvie.com[30]
• news.abbvie.com[31]
• news.abbvie.com[32]
• AbbVie Inc. — Full financial report (2020 Q 2)[33]
• news.abbvie.com[34]